An Eli Lilly pharmaceutical manufacturing plant at 50 ImClone Drive in Branchburg, New Jersey, on March 5, 2021. Mike Segar/Reuters
Eli Lilly has announced agreements to acquire three vaccine-focused biotech companies in deals worth up to $3.83 billion, expanding the drugmaker’s infectious disease portfolio.
The company said on May 26 it will acquire Washington state-based Curevo, Swiss biotech LimmaTech Biologics, and Maryland-based Vaccine Company, with all three deals including an upfront payment and milestone payments.
